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ABSTRACT 
 
Miconazole nitrate (MIC) is an antifungal drug used for treatment of superficial fungal infections. However, 
it has low skin permeability. Hence, the basic idea behind the development of such a system, transfersomes 
is to maintain a sustain release of drug from the dosage form and for target delivery. Miconazole nitrate was 
formulated as transfersomes, half-life can be increased and the desired effect can be obtained. MIC transfer-
somes were prepared using a thin lipid film hydration technique. The prepared transfersomes were evalu-
ated with respect to entrapment efficiency (EE%), particle size, and quantity of in vitro drug released to 
obtain an optimized formulation. The optimized formulation of MIC transfersomes was incorporated into a 
Carbapol 934 gel base which was for drug content, pH, spreadability, viscosity, in vitro permeation, and in 
vitro activity. The prepared MIC transfersomes had a high EE% ranging from 65.45% to 80.11%, with small 
particle sizes ranging from 368 nm to 931 nm. The in vitro release study suggested that there was an inverse 
relationship between EE% and in vitro release. In 24 hrs the drug release was observed ranging from 
79.08% to 88.72%. The kinetic analysis of all release profiles was found to follow Higuchi’s diffusion model. 
All independent variables had a significant effect on the dependent variables (p-values < 0.05). Therefore, 
Miconazole nitrate in the form of transfersomes has the ability to penetrate the skin, overcoming the stratum 
corneum barrier. When the data subjected to zero order and first order kinetics model, a linear relationship 
was observed with high R2 values for zero order model as compared to first order model and suggested that 
the formulations followed zero order sustained release. 
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INTRODUCTION 
Miconazole topical is an antifungal medication. 
Miconazole topical prevents fungus from growing on 
your skin. Miconazole topical (for the skin) is used to 
treat skin infections such as athlete's foot, jock itch, 
ringworm, tinea versicolor (a fungus that discolors 
the skin), and yeast infections of the skin. Miconazole 
topical may also be used for purposes not listed in 
this medication guide. The antifungal agent used top-
ically often in its nitrate form, to treat candidiasis and 
other fungal infections is known as Miconazole ni-
trate.[1] 
The development of a new drug delivery system has 
been of great interest. The purpose of the novel drug 
delivery system is to deliver the drug to the body's 
needs during the treatment cycle and to redirect the 
active agent to the action site. There have been a 
number of new drug delivery systems which cover 
many administrative routes to ensure managed and 
targeted distribution. One such method is the encap-
sulation of a drug in vesicular structures, which could 
be expected to extend the life of the drug in systemic 
circulation and minimize toxicity if the drug can be 
chosen. A variety of vesicular systems have therefore 
been developed for the delivery of drugs, such as lip-
osomes, niosomes, pharmacosomes and transfer-
somes. The use of liposomal, transfersome vesicular 
systems, as well as the ability to integrate hydrophilic 
and lipophilic medicines are one of the options for im-
proving the penetration of drugs in the skin. 
Recent strategies in drug delivery include distrib-
uting the medication at a default rate known as the 
controlled release delivery system. Such devices also 
helped to reduce the side-effects of the conventional 
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multidose therapy program. Due to the various ad-
vantages this administration route provides, the pro-
duction of transdermal dosage forms has been at-
tracting growing attention in recent years. Transder-
mal delivery system generally shows better regula-
tion of blood levels, decreased occurrence of systemic 
toxicity, no first-pass hepatic metabolism, and higher 
compliance as compared with conventional formula-
tions. Transdermal treatment systems are character-
ized as self-containing and discrete dosage types, 
which supply the medication with a regulated rate of 
systemic circulation through the skin if applied to the 
intact skin.[2] 
The medication system provides a range of potential 
benefits over traditional routes, such as the preven-
tion of first-pass metabolism, predictable and ex-
tended activity, short-term use of medicines, im-
proved physiological or drug responses, a reduction 
in negative side-effects, avoided fluctuations in drugs 
levels, inter-patient and intra-patient variations and, 
most importantly, minimized adverse effects.[3] A va-
riety of methods in the field of medical research have 
been used to improve the effectiveness of material 
across to intact skin using penetrators, enhancers, 
ionotophoresis, sonophoresis and vesicular construc-
tions. The word "vesicular constructs" is used with 
liposomes, niosomes, virosomes, ethosomes and 
transfersomes.[4] 
Transfersomes were designed to benefit from phos-
pholipid vesicles as a transdermal medication’s car-
rier. Transferosomes overcome the problem of skin 
penetration by rubbing the intracellular lipid of the 
corneum of the stratum. Due to the high deformation 
of the vesicle, this is possible due to the external me-
chanical stress. This enables entry in a self-adjusting 
manner. The resulting flexibility in the Transfer-
somes membrane reduces the risk that the skin will 
be rupture completely and allows transfersomes to 
follow the natural water gradient in a non-occluding 
condition throughout the epidermis.[5] The Transfer-
somes can spontaneously penetrate the intact stra-
tum corneum via two intracellular, bilayer-variable 
lipid pathways. 
Transfersomes, a new class of modified liposomes 
were derived from the Latin word “transfer”, And the 
Greek word "soma" meaning “a body. “Transfer-
somes, which are initially reported by Cevc[6] and are 
different descriptions of deforming, highly-deforma-
ble, elastic or ultra-flexible liposomes are claimed to 
improve transdermal, in vitro delivery of a wide range 
of drugs and are defined as non-natural vesicular de-
signed to display an attribute of cell vesicle or cell en-
gaged in exocytosis.[7] The deformation of trans-
ferosomes is the result of integration of the edge acti-
vator into the bilayer phospholipids which increases 
elasticity through the destabilization of lipid bi-
layers.[8] Edge activators are commonly used as sin-
gle-chain surfactants such as sodium cholate and 
tween 80.[9,10] Transfersomes will squeeze around 
one-tenth of the diameter of the vesicles through con-
duits and allow them to spontaneously enter the stra-
tum corneum.[11] 
 
Figure 1: Structure of Transfersomes[13] 
MATERIALS AND METHODS  
Materials 
Miconazole Nitrate was obtained as a gift sample 
from vital Laboratories Pvt. Ltd, soya lecithin was 
purchased from Himedia, and methanol was pur-
chased from Fischer Scientifics, Span 80 and tween 
80 was procured from Reachem, Mumbai., India and 
Carbopol 934 was procured from Loba Chamoe Pvt 
Ltd, Mumbai 
Preparation of Miconazole nitrate Loaded Trans-
fersomes 
Soya-phosphatidylcholine was taken in a round bot-
tom flask. Span80 (sp) or Tween 80 (Tw) was put in 
the same round bottom flask. Methanol was then 
added to the same flask. The Miconazole nitrate was 
also loaded in the same RBF. These were then dis-
solved by shaking. Thin film was then formed by 
keeping it in the rotatory vacuum evaporator at 600C. 
To prepare small vesicles, resulting LMVs were soni-
cated at room temperature or 500C for 30min. the 
sonicated vesicles were homogenized by manual ex-
trusion 10 times through a sandwich of 200 and 
100nm polycarbonate membrane. Then finally we got 
the Transferosome were transferred to 2% w/v car-
bopol gel. 
Preparation of Gels  
Preparation of carbopol gel base: 0.5 g Carbopol 
934 was weighed and dispersed in water with mild 
stirring and allowed to swell for 24 hours to obtain 
0.5% gel. Later 2 ml of glycerin was added to for gel 
consistency. As shown in the (Table 1) different com-
positions of Carbopol 0.5, 1 and 2% gels were pre-
pared.[12]  
Table 1: Composition of different gel base 
Formulation Carbopol (%) 
TF1 0.5 
TF2 1.0 
TF3 2.0 
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Evaluation of miconazole nitrate transfersomes 
Drug- Excipient Compatibility  
Differential scanning Calorimetry (D.S.C): Differ-
ential Scanning Calorimetry (DSC) is used to check 
the compatibility of drug with excipients. DSC meas-
urements were done on pyris calorimeter. Approxi-
mately 3-5mg of drug were weighed accurately a into 
standard aluminum pan. An empty pan was used as a 
reference. The samples were heated from room tem-
perature to 390°C with scan rates 10°c/minute. Then 
the DSC curves are recorded with the help of com-
puter scans. [14]  
Fourier transforms infrared spectroscopy (FT-
IR): FTIR spectroscopy was carried out to check the 
compatibility between the drug and polymer. The IR 
spectra of Miconazole Nitrate and physical mixtures 
of drug and polymer was carried out by using FTIR, 
Bruker. The scanning range was 400 to 4000 cm-1 and 
the resolution was 1 cm-1. The wave numbers of char-
acteristic peaks of physical mixtures were compared 
with the pure samples and interpreted. [15] 
Vesicle morphology: For SEM one drop of Transfer-
somes were mounted on the stab covered with clean 
glass and coated with gold and were observed under 
the scanning electron microscope at an accelerating 
voltage of 20KV and photomicrographs of suitable 
magnification was obtained. 
Particle size: Size was determined using a Zetasizer 
300HS. Samples were diluted with distilled water and 
measured at a temperature of 25ºC. The diameter was 
calculated from the autocorrelation function of inten-
sity of light scattering from transferosomes. [16] 
Drug content: 1gm each formulation containing ap-
proximately 40mg of drug was taken in a 50 ml volu-
metric flask and diluted with methanol and shaken to 
dissolve the drug in methanol. The solution was fil-
tered through Whatmann filter paper, 0.1 ml of the 
filtrate was pipette out and diluted 10ml of methanol. 
The content of the drug was observed in UV-Spectro-
photometer. [17, 18] 
Entrapment Efficiency: The concentration of Micon-
azole nitrate in the formulation was determined by 
UV analysis after disruption of the vesicles with Tri-
ton X-100 (0.5% w/w). The vesicle/Triton X-100 so-
lution was centrifuged at 10,000 rpm at 40C for 10 
min. The supernatant was filtered. The entrapment 
efficiencies and the loading efficiencies of the Micon-
azole nitrate-loaded formulation were calculated by 
UV. [19] 
Entrapment efficiency =  (
Amount entrapped
Total amount added
) × 100 
In vitro drug release studies  
The in vitro permeation behaviour of Miconazole ni-
trate from all transfersomal gel formulations and the 
control gel formulation (containing drug, span 80, 
Tween 80, and Soya phosphatidylcholine) were in-
vestigated using cellophane membrane (Molecular 
weight cut of 12000–14000). The vertical type of the 
Franz Diffusion cell was designed, fabricated, and val-
idated prior to the permeation study. The cellophane 
membrane was mounted on a diffusion cell assembly 
with an effective diffusion area of 2.303 cm2. The re-
ceptor compartment consisted of a 22.5 ml phos-
phate buffer at pH 7.4 as the receptor fluid agitated at 
100 rpm, and was maintained at 37 ± 0.5°C through-
out the experiments. The prepared formulation was 
applied to the membrane in the donor compartment. 
An aliquot of 2 mL sample was withdrawn at suitable 
time intervals and replaced immediately with an 
equal volume of fresh diffusion medium. The cumula-
tive amount that permeated across the cellophane 
membrane was calculated and plotted against time. 
[20, 21] 
Kinetics of drug release: To examine the drug re-
lease kinetics and mechanism the cumulative release 
data were fitted to models of data treatment as fol-
lows: 
• Cumulative percentage drug release Vs. Time 
(zero order rate kinetics) 
• Log cumulative percentage drug retained Vs. 
Time (first order rate kinetics) 
Table 2: Formulation chart of Miconazole nitrate loaded transferosomal gel 
Formulation 
Code 
Composition 
Drug 
(mg) 
Lecithin 
(mg) 
Span80 
(mg) 
Tween80 
(mg) 
Methanol 
(ml) 
Phosphate 
buffer (ml) 
F1 10 95 5 - 2 10 
F2 10 90 10 - 2 10 
F3 10 85 15 - 2 10 
F4 10 80 20 - 2 10 
F5 10 75 25 - 2 10 
F6 10 70 30 - 2 10 
F7 10 95 - 5 2 10 
F8 10 90 - 10 2 10 
F9 10 85 - 15 2 10 
F10 10 80 - 20 2 10 
F11 10 75 - 25 2 10 
F12 10 70 - 30 2 10 
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• Cumulative percentage drug release Vs. SQRT 
(Higuchis classical diffusion equation) 
• Log of cumulative percentage drug release Vs. 
log time (Peppa’s exponential equation). 
RESULTS AND DISCUSSION  
A successful attempt was made formulate trans-
ferosomes gel of Miconazole nitrate using different 
surfactants. Effect of surfactant applied on formula-
tions was assessed. In the present work, twelve for-
mulations were prepared and composition is men-
tioned in table. Among these one of the best formula-
tions was loaded into carbopol gel. The formulated 
transferosomes and gel were characterized for vari-
ous physicochemical parameters. 
Preformulation studies of pure drug: 
Drug excipients compatibility studies 
Chemical compatibility-Differential scanning cal-
orimetry (DSC) studies: The DSC procedure is fol-
lowed and DSC thermogram of API, drug-Excipient 
compatibility blend were shown in the (Figure 2 and 
Figure 3).  
 
Figure 2: DSC Thermogram of Miconazole Nitrate 
(API) 
 
Figure 3: DSC Thermogram of Miconazole Nitrate 
(API) + Excipient 
Identification of Miconazole nitrate: The IR spec-
trum of pure drug was found to be similar to that of 
standard spectrum of Miconazole nitrate. The spec-
trum of Miconazole nitrate shows the following 
groups at their frequencies shown in 1473, 1642, 
2904, 3407 cm-1. Determination of melting point. The 
melting point of Miconazole nitrate was found to be 
170-184°C which complied with the BP standards. 
Drug-polymer compatibility: Compatibility studies of 
pure drug Miconazole nitrate with polymers were 
carried out prior formulation of transferosomes. IR 
spectra of pure drug and polymer were taken. All the 
characteristic peaks of Miconazole nitrate were pre-
sent in spectra at respective wavelength. As shown in 
(Figure 4, Figure 5, Figure 6, Figure 7) Thus, indicat-
ing compatibility between drug and polymers were 
interpretation was represented in (Table 3) and  It 
shows that there was no significant change in the 
chemical integrity of the drug. 
 
Figure 4: FTIR of Miconazole nitrate drug 
 
Figure 5: FTIR of Miconazole nitrate+ Soya Lecithin 
 
Figure 6: FTIR spectra of Pure Miconazole nitrate + 
Span 80 
 
Figure 7: FTIR spectra of Pure Miconazole nitrate + 
Tween 80 
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Morphology: The prepared transferosomes were un-
dergone morphological studies by using optical mi-
croscopic method. Small quantity of sample spreaded 
over clean slide. The slide was focused under optical 
light and images were snapped by using optical mi-
croscopy attached with Dewinter Microscopic cam-
era software. According to morphological evaluation 
analysis, all vesicles types seemed to have a spherical 
or oval shaped which had been resulted or shown in 
(Figure 8). These oval-shaped vesicles may have re-
sulted from the transferosomes’ deformation, which 
might occur during the sample preparation. 
 
Figure 8: SEM image of transferosomes 
Particle size: Particle size analysis showed that the 
sizes of different formulations were in the range of 
368 nm and 931 nm indicating that these vesicles 
were all of a small size. From formulation F1 to F12 
particle size are listed in (Table 4) 
Drug content: Drug content uniformity was deter-
mined as triplicate by dissolving in methanol and dis-
solved transferosomes were undergone centrifuga-
tion at 3000rpm for 2hrs and filtered with Whatmann 
filter paper (0.45,) Whatman, Maidstone, UK). The so-
lution was diluted to Beer’s range and observed in 
UV-Spectrophotometer). The value range from 
80.45% to 94.15% as shown in (Table 4). 
 
Figure 9: Entrapment Efficiency of F1 to F12 Formula-
tions 
Entrapment Efficiency 
The entrapment efficiency of deformable vesicles for-
mulations were found to be in the range of 66.12 to 
80.11. The percentage entrapment efficiency for 
span80 was maximum F3 for i.e. 80.11 and minimum 
for F6 i.e. 65.41 and in case of tween80 maximum for 
F10 i.e. 74.25 and minimum for F8 i.e. 66.12%. as 
shown in (Figure 9). 
Table 4: Particle size, Entrapment Efficiency of F1 to 
F12 Formulations 
S. 
No 
Formula-
tion 
Code 
Particle 
size 
(nm) 
Drug con-
tent 
(%) 
Entrap-
ment 
Efficiency 
(%) 
1 F1 620 87.65 74.14 
2 F2 741 81.43 69.42 
3 F3 368 88.91 80.11 
4 F4 721 90.31 71.78 
5 F5 866 87.41 70.65 
6 F6 871 94.15 65.41 
7 F7 644 83.46 69.12 
8 F8 702 80.45 66.12 
9 F9 794 89.14 72.44 
10 F10 462 85.16 74.25 
11 F11 866 84.25 68.36 
12 F12 931 88.16 72.11 
In vitro Diffusion Studies 
In vitro diffusion studies of all the formulation of 
transferosomes of Miconazole nitrate were carried 
out in pH 7.4 phosphate buffer. The study was per-
formed for 24hrs and cumulative percentage drug re-
lease was calculated at different time intervals. The in 
vitro drug release profile for the formulation (F1 to 
F6), (F7 to F12) were tabulated in (Table 5 and Table 
6) . The plot of time Vs cumulative % drug release for-
mulations (F1 to F6) to (F7 to F12) were plotted and 
depicted in (Figure 10 and Figure 11)figures. Effects 
of various surfactants and their concentration on 
drug release were studied. 
In vitro drug release studies from gel through a 
cellophane membrane: 
Transferosomal gel formulation was subjected to in 
vitro drug release studies using a cellophane mem-
brane. The cumulative amount of drug release was 
calculated. Results revealed that highest cumulative 
amount of drug release 88.62% up to 24hrs.  
Table 3: Interpretation of Miconazole nitrate and physical mixtures 
S.no 
Type of 
bond 
Type of 
stretch 
IR absorption bands (cm-1)  
Characteris-
tic peak 
Pure Drug (Micon-
azole Nitrate) 
Physical Mixture 
(drug + span80 + 
soya lecithin) 
Physical Mixture 
(drug + tween80 + 
soya lecithin) 
1 N-H Stretch 3500-3300 3407.74 3361.60 3398.91 
2 C-H Stretch 2960-2850 2904.48 2925.55 2915.42 
3 C=O Stretch 1600-1900 1642.87 1738.52 1739.21 
4 C-C Stretch 1450-1070 1473.41 1055.63 1067.25 
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Figure 10: In-vitro Diffusion studies for F1 to F6 
 
Figure 11: In-vitro diffusion studies for F7 to F12 
 
Figure 12: Time Vs Drug retained (First order kinetics) 
of formulations F1 to F6 
 
Figure 13: Time Vs Drug retained (First order kinetics) 
of formulations F7 to F12 
Table 5: In vitro percentage Cumulative drug release of F1 to F6 
S.No Time (Hrs) 
% Cumulative drug release 
F1 F2 F3 F4 F5 F6 
1 0 0 0 0 0 0 0 
2 1 12.54±0.02 13.50±0.48 16.87±0.09 13.27±0.25 11.44±0.12 11.68±0.01 
3 2 20.66±0.22 16.09±0.25 20.41±0.24 23.36±0.31 27.57±0.25 23.48±0.05 
4 3 29.99±0.35 20.82±0.43 23.99±0.26 26.91±0.16 30.13±0.19 27.96±0.09 
5 4 32.57±0.02 29.01±0.38 27.60±0.06 31.60±0.09 37.29±0.24 34.61±0.1 
6 5 39.73±0.12 32.72±0.27 33.49±0.09 35.22±0.13 42.23±0.35 39.20±0.33 
7 6 41.26±0.28 38.74±0.36 38.31±0.35 39.99±0.38 46.08±0.29 42.77±0.42 
8 7 48.51±0.24 44.82±0.25 45.43±0.24 42.59±0.46 48.81±0.31 45.31±0.21 
9 8 51.26±0.32 50.96±0.34 51.50±0.29 50.74±0.24 52.71±0.19 48.93±0.32 
10 12 64.30±0.15 60.58±0.09 60.99±0.32 61.18±0.5 62.37±0.41 57.89±0.44 
11 24 82.03±0.27 81.69±0.19 79.57±0.45 87.21±0.19 85.84±0.22 81.81±0.49 
Table 6: In vitro percentage Cumulative drug release of F7 to F12 
S.No Time (Hrs) 
% Cumulative drug release 
F7 F8 F9 F10 F11 F12 
1 0 0 0 0 0 0 0 
2 1 16.77±0.15 19.88±0.09 15.70±0.09 21.13±0.09 13.05±0.1 19.28±0.16 
3 2 31.32±0.18 28.78±0.1 20.35±0.12 24.87±0.06 17.93±0.16 24.01±0.19 
4 3 32.83±0.26 34.04±0.14 27.28±0.19 28.64±0.12 25.23±0.24 28.78±0.1 
5 4 37.94±0.33 39.35±0.24 32.03±0.24 33.61±0.17 30.23±0.32 35.87±0.24 
6 5 41.91±0.28 42.22±0.35 40.20±0.31 42.16±0.21 32.90±0.19 44.16±0.29 
7 6 48.31±0.39 50.09±0.29 45.08±0.22 46.10±0.26 39.15±0.25 49.13±0.22 
8 7 51.17±0.45 53.06±0.14 47.76±0.29 47.72±0.32 47.84±0.35 53.01±0.34 
9 8 60.05±0.42 63.51±0.32 51.59±0.24 54.05±0.41 51.86±0.12 56.93±0.19 
10 12 71.41±0.46 74.07±0.28 62.18±0.45 65.13±0.34 63.05±0.25 65.41±0.45 
11 24 87.67±0.49 88.45±0.26 82.97±0.24 83.37±0.45 79.08±0.29 88.72±0.49 
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Figure 14: Square root of Time Vs % Cumulative Drug 
Released (Higuchi Release mechanism) of Formulation 
F1 to F6 
 
Figure 15: Square root of Time Vs % Cumulative Drug 
Released (Higuchi Release mechanism) of Formulation 
F7 to F12 
 
Figure 16: Log Time Vs Cumulative % Drug Released 
(Korsmeyer-Peppas Release Mechanism) of Formula-
tions F1 to F6 
 
Figure 17: Log Time Vs Cumulative % Drug Released 
(Korsmeyer-Peppas Release Mechanism) of Formula-
tions F7 to F12 
 
Figure 18: Time Vs % Cumulative drug release (Zero 
order kinetics) of F3 Formulation Gel 
SUMMARY 
Miconazole nitrate is mainly used in the treatment of 
fungal infections. The basic idea behind the develop-
ment of such a system is to maintain a sustain release 
of drug from the dosage form and for target delivery. 
In the research work an attempt was made to formu-
late and evaluated the transferosomal gel for sus-
tained effect. The drug excipient compatibility stud-
ies were carried out by using DSC & FT-IR technique. 
Based on the results, excipients were found to be 
compatible with Miconazole nitrate. In preformula-
tion study, estimation of Miconazole nitrate was car-
ried out by U.V spectrophotometer at λ max 272 nm 
using water as solvent, which had a good reproduci-
bility and this method was used entire study. Entrap-
ment efficiency ranging from 65.45 to 80.11% was 
obtained. Particle size of transferosomes was found 
to be in the range of 368 to 931 nm. In 24 hrs the drug 
release was observed ranging from 79.57% to 
88.72%. Drug release from the gel was observed that 
79.57%. In order to reduce the probable mechanism 
of drug from the dosage form, the result of in vitro dis-
solution studies were fitted to various kinetics equa-
tions. When the data subjected to zero order and first 
order kinetics model, a linear relationship was ob-
served with high R2 values for zero order model as 
compared to first order model and suggested that the 
formulations followed zero order sustained release. 
CONCLUSION 
Transferosomal drug delivery system offers a simple 
and practical approach to achieved increase bioavail-
ability, avoids first pass metabolism and modify drug 
release profiles essential for sustained, site specific 
and localized drug action. In vitro release obeyed zero 
order kinetics with mechanism of release zero order 
followed by non fickian diffusion due to more lipo-
philic nature of polymers used. The drug permeation 
was slow and study and 79.57% of Miconazole nitrate 
could permeate through the skin into the piloseba-
ceous unit in 24hrs. Among all the formulations, F3 
possess satisfactory swelling index, and in vitro drug 
release studies were extended period of time so F3 
was considered to be the best formulations. So, 
Miconazole nitrate used for the treatment of pain as 
transferosomal gel can produce fast absorption. The 
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study conducted so far reveals promising result sug-
gesting scope for pharmacodynamic and pharmaco-
kinetics evaluation. 
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